This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Two cases were recently reported in THE JOURNAL of health care workers with possible exposure to the human immunodeficiency virus (HIV) who developed adverse reactions after receiving multiple doses of nevirapine, zidovudine, and lamivudine as a postexposure prophylaxis (PEP) regimen.^1-2 One patient developed fulminant hepatic failure resulting in liver transplant, and the other patient developed rash, eosinophilia, and other systemic symptoms. Both patients have since recovered. The authors believe that nevirapine was responsible for both these adverse reactions, although the precise etiology of these reactions is unknown. Since no clinical trials have been conducted that would assess the risks or establish the efficacy of using nevirapine for PEP, the risks remain undefined. Postexposure prophylaxis is not an approved indication for nevirapine and Boehringer Ingelheim (BI) does not recommend using it for PEP.

Both of the cases were described as acute hypersensitivity reactions. In patients treated with nevirapine, . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Commentary
van Ryn and Williams
Med Care Res Rev 2003;60:496-508.
 

Paved With Good Intentions: Do Public Health and Human Service Providers Contribute to Racial/Ethnic Disparities in Health?
van Ryn and Fu
AJPH 2003;93:248-255.
ABSTRACT | FULL TEXT